Grand Pharmaceutical Group Ltd
Company Profile
Business description
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Contact
99 Queen's Road Central
Units 3302, 33rd Floor, The Center
Hong Kong
HKGSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
12,614
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,399.27 | 32.34 | -0.38% |
| DAX 40 | 24,786.01 | 208.82 | -0.84% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,487.16 | 42.73 | -0.41% |
| HKSE | 22,684.09 | 392.82 | -1.70% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,357.49 | 0.73 | -0.01% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |